



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Università degli Studi di Padova

Padua Research Archive - Institutional Repository

Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric

Original Citation:

Availability:

This version is available at: 11577/3344157 since: 2020-07-02T23:26:49Z

Publisher:

WILEY

Published version:

DOI:

Terms of use:

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)

ABSTRACT NUMBER: 53

Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study

Maria Chiara Gerardi¹, Alberto Batticciotto², Rossella Talotta¹, Maria Chiara Ditto¹, Fabiola Atzeni² and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cannabinoid, Effective, Fibromyalgia and treatment

SESSION INFORMATION

Date: Sunday, November 13, 2016

Session Type: ACR Poster Session A

Session Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

Session Time: 9:00AM-11:00AM

Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study

Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, sleep and affective disturbances. Treatment is based on the symptomatic relief of symptoms but only modest results are achieved. There are few evidences on the effectiveness of cannabinoids in the improvement of FM symptoms. A cannabinoid (Cannabis flos 19%), containing tetrahydrocannabinolic acid 19% and cannabidiolic acid <1% used as orally decoction, is available in Italy for treating chronic pain. The aim of the this study was to evaluate the efficacy of Cannabis flos 19% on pain, fatigue, sleep disturbances, anxiety and depression in FM patients.

Methods: Fifteen patients affected by FM according to the ACR 2010 criteria and treated with Cannabis flos 19% (30 mg twice a day for the first month, 60 mg twice a day for the second month), have been evaluated at baseline and after 2 months of treatment with the following questionnaires: the Fibromyalgia Impact Questionnaire revised (FIQR), the Fibromyalgia Activity Score (FAS), the Functional Assessment of Chronic Illness Therapy (FACIT), the Pittsburgh Sleep Quality Index (PSQI), the Zung Self-Rating Anxiety Scale (ZS-RA) and the Zung Self-Rating Depression Scale (ZS-RD).

Results: Table 1 shows the demographic and clinical characteristics of the patients involved in study. 11/15 patients completed the 2-months follow up. After 2 months of treatment a statistical significant improvement in the terms of medians values of VAS pain (8.2 ± 1 vs 6.2 ± 2.4 , $p = 0,0273$), FAS (7.8 ± 1.7 vs 6.2 ± 2.1 , $p = 0,0494$), FACIT (13.5 ± 7.4 vs 22.9 ± 10.5 , $p = 0,0042$), ZR-SA (66.2 ± 14 vs 57.6 ± 13.3 , $p = 0,0172$) and ZS-RD (58 ± 10.3 vs 48.7 ± 11.5 , $p = 0,0491$) has been found; while the median FIQR scores (74.4 ± 17.2 vs 60.3 ± 24.3 , $p = 0,0615$) and sleep disturbances scores (PSQI, 11 ± 2.8 vs 10.5 ± 3.8 , $p = 0,5435$) didn't change. Two patients (13%) stopped the treatment for inefficacy. Furthermore, although adverse events range from mild to moderate two patient stopped the treatment: one for the appearance of confusion and sweating and one for the mood deflection.


Conclusion: This study showed that Cannabis flos 19% is effective in improving pain, fatigue, anxiety and depression in FM patients. Further studies are suggested in order to confirm this preliminary data on efficacy and safety of this therapy for treating FM patients. **Table 1. Demographic and clinical characteristics of FM patients**

	FM patients (n=15)
Age, median (IQR)	53(50-54)
Female/Male	13/2
BMI, median (IQR)	26.6 (22-29)
No smokers, n(%)	4(27)
Ever smokers, n(%)	3(20)
Smokers, n(%)	8(53)
Disease duration (<i>months</i>), median (IQR)	180 (120-240)
Treatment, n (%)	
Pregabalin	2 (13)
Duloxetine	7 (47)
Amitriptyline	1 (7)
Tramadol	4(27)
Tapentadol	2 (13)
Others SNRIs	2(13)
Others opioids	3(20)
Benzodiazepine	4(27)

Table 1. Demographic and clinical characteristics of population

	FM patients (n=15)
Age, median (IQR)	53(50-54)
Female/Male	13/2
BMI, median (IQR)	26.6 (22-29)
No smokers, n(%)	4(27)
Ever smokers, n(%)	3(20)
Smokers, n(%)	8(53)
Disease duration (months), median (IQR)	180 (120-240)
Treatment, n (%)	
Pregabalin	2 (13)
Duloxetine	7 (47)
Amitriptyline	1 (7)
Tramadol	4(27)
Tapentadol	2 (13)
Others SNRIs	2(13)
Others opioids	3(20)
Benzodiazepine	4(27)

Figure 1. Significant improvement on VAS pain, FAS, FACIT, ZR-SA and ZR-SD



Disclosure: M. C. Gerardi, None; A. Batticciotto, None; R. Talotta, None; M. C. Ditto, None; F. Atzeni, None; P. Sarzi-Puttini, None.

To cite this abstract in AMA style:

Gerardi MC, Batticciotto A, Talotta R, Ditto MC, Atzeni F, Sarzi-Puttini P. Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study [abstract]. *Arthritis Rheumatol.* 2016; 68 (suppl 10). <https://acrabstracts.org/abstract/efficacy-of-cannabis-flos-in-patients-with-fibromyalgia-a-monocentric-observational-study/>. Accessed July 2, 2020.

ACR Meeting Abstracts - <https://acrabstracts.org/abstract/efficacy-of-cannabis-flos-in-patients-with-fibromyalgia-a-monocentric-observational-study/>

This site uses cookies: [Find out more.](#)

Okay, thanks